ArticleFrontiers in oncology2026
Microdosimetric characterization of proton relative biological effectiveness in pancreatic ductal adenocarcinoma cell lines.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is among the most radioresistant malignancies. Proton therapy assumes a uniform relative biological effectiveness (RBE) of 1.1 regardless of radiation quality. We characterized proton RBE as a function of dose-mean lineal energy ( Methods: Proton RBE was assessed in Panc-1 and COLO 357 FG cells using a high-throughput 96-well irradiation platform with an 81.4 MeV spot-scanning proton beam. Cells were irradiated at 12 discrete depths along the pristine Bragg curve, spanning Results: Both cell lines demonstrated RBE near 1.0 at entrance energies ( Conclusions: The clinical RBE = 1.1 assumption substantially underestimates proton effectiveness in the distal Bragg peak region for PDAC. This microdosimetric RBE dataset provides a quantitative basis for improving proton treatment planning in radioresistant PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.